3 Reasons I Bought More Realty Income Before Earnings And So Should You
Realty Income's management, led by CEO Sumit Roy, leverages private equity expertise to drive long-term growth of 5% to 6% ...
AbbVie Inc. stock outperforms competitors on strong trading day
Shares of AbbVie Inc. ABBV rose 1.79% to $200.88 Thursday, on what proved to be an all-around poor trading session for the ...
stocknews2d
3 REITs Benefiting from the Remote Work Era
The rise of remote work is transforming real estate, driving demand for flexible workspaces, data centers, and suburban ...
AbbVie Appears Ready To Move Higher
AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...
How Is The Market Feeling About AbbVie?
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...
Why AbbVie Inc. (ABBV) Is One of the Best Drug Stocks to Buy Now
Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...
AbbVie Full Year 2024 Earnings: EPS Misses Expectations
Full Year 2024 Results Key Financial Results Revenue: US$56.3b (up 3.7% from FY 2023). Net ...
stocknews7d
3 Tech Stocks Under $50 with Upside Potential
Driven by rising demand and investment in technological innovation, the tech industry's future looks promising. In this ...
Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs
Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell engagers, with $52.0 million in upfront payments Extended ant ...
AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies
Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell ...